NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year High – Time to Buy?

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $42.21 and last traded at $41.59, with a volume of 528706 shares trading hands. The stock had previously closed at $38.73.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Needham & Company LLC upped their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Royal Bank Of Canada upped their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective for the company. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.00.

NewAmsterdam Pharma Stock Up 2.2%

The stock’s 50-day moving average price is $31.77 and its 200 day moving average price is $34.24. The firm has a market cap of $4.55 billion, a price-to-earnings ratio of -22.12 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The company had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.81 EPS for the current year.

Insider Buying and Selling

In related news, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the transaction, the chief executive officer owned 174,144 shares of the company’s stock, valued at $5,790,288. This represents a 71.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the completion of the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at $2,099,850.60. This trade represents a 60.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,168,286 shares of company stock valued at $38,211,967 over the last quarter. Corporate insiders own 12.74% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its position in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN raised its position in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV acquired a new position in NewAmsterdam Pharma in the first quarter worth about $37,000. Navalign LLC acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $46,000. Finally, Empowered Funds LLC acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $85,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.